<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000301627"><TermName>tariquidar</TermName><TermPronunciation>(tar-IH-kwih-dar)</TermPronunciation><TermDefinition><DefinitionText>A substance that is being studied in the treatment of cancer. It may help tumor cells respond again to drugs they have become resistant (unable to respond) to. Tariquidar is a type of multidrug resistance inhibitor and a type of P-glycoprotein antagonist. Also called XR9576.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000709870" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tariquidar&quot;" language="en" id="_3"/><MediaLink ref="CDR0000709869" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tariquidar&quot;" language="es" id="_4"/><SpanishTermName>tariquidar</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Puede ayudar a que las células tumorales respondan nuevamente a los medicamentos a los que se han vuelto resistentes (incapaces de responder). El tariquidar es un tipo de inhibidor de la resistencia a múltiples medicamentos y un tipo de antagonista de la glucoproteína-P. También se llama XR9576.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2003-04-23</DateFirstPublished><DateLastModified>2008-07-22</DateLastModified></GlossaryTerm>
